S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NASDAQ:CBMX

129916 Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$6.25
0.00 (0.00 %)
(As of 11/16/2017)
Add
Today's Range
$6.25
Now: $6.25▼
$6.25
50-Day Range N/A
52-Week Range
$2.20
Now: $6.25▼
$8.20
VolumeN/A
Average Volume119,111 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CBMX
Previous Symbol
CUSIPN/A
CIK1383183
Webcombimatrix.com
Phone+1-949-7530624
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CBMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











129916 (NASDAQ:CBMX) Frequently Asked Questions

What stocks does MarketBeat like better than 129916?

Wall Street analysts have given 129916 a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 129916 wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were 129916's earnings last quarter?

129916 (NASDAQ:CBMX) issued its quarterly earnings data on Monday, November, 6th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The medical research company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. During the same period in the previous year, the firm earned ($0.38) EPS.
View 129916's earnings history.

When did 129916's stock split? How did 129916's stock split work?

129916's stock reverse split on Monday, February 1st 2016. The 1-15 reverse split was announced on Wednesday, January 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2016. An investor that had 100 shares of 129916 stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of 129916 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 129916 investors own include Vermillion (VRML), Charter Communications (CHTR), InspireMD (NSPR), CorMedix (CRMD), BIOLASE (BIOL), Glu Mobile (GLUU), GTX (GTXI), Microbot Medical (MBOT), Navidea Biopharmaceuticals (NAVB) and (PRSNQ) (PRSNQ).

Who are 129916's key executives?

129916's management team includes the following people:
  • Robert Judd Jessup, Chairman of the Board (Age 68)
  • Mark McDonough, President, Chief Executive Officer, Director (Age 46)
  • Scott R. Burell, Chief Financial Officer, Treasurer, Secretary (Age 52)
  • Dirk van den Boom Ph.D., Director (Age 47)
  • Robert E. Hoffman, Independent Director (Age 51)
  • Jeremy M. Jones, Independent Director (Age 75)
  • Lale White, Independent Director (Age 60)

What is 129916's stock symbol?

129916 trades on the NASDAQ under the ticker symbol "CBMX."

What is 129916's stock price today?

One share of CBMX stock can currently be purchased for approximately $6.25.

What is 129916's official website?

The official website for 129916 is combimatrix.com.

How can I contact 129916?

129916's mailing address is 310 Goddard Ste 150, IRVINE, CA 92618-4617, United States. The medical research company can be reached via phone at +1-949-7530624.

This page was last updated on 11/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.